Cost effectiveness of antenatal anti-D prophylaxis
研究评估了不同剂量产前抗D预防方案的成本效益，发现针对初产妇的方案比针对所有Rh阴性女性的方案更具成本效益，其中1250国际单位剂量方案最优。
This paper estimates the incremental cost-effectiveness of providing antenatal anti-D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 'at risk' women based on the costs of anti-D prophylaxis and the future NHS costs avoided. Incremental cost-effectiveness is measured in terms of the net cost per Rh D-alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost-effective than the same dose protocol extended to all Rh D negative women. The 1 x 1250 iu programme is the most cost-effective option.